

# THE VALUE OF THE DENGUE VACCINE A NEW PREVENTION TOOL IN THE FIGHT AGAINST A HIGH DISEASE BURDEN IN THE PHILIPPINES



## ESTIMATED NUMBER OF DENGUE CASES IN 2013


**200,000**  
reported cases<sup>(2)</sup>

**1.2 MILLION**

estimated with under-reporting<sup>(1)</sup>  
by a factor of **11x** for ambulatory  
cases and **5x** for hospitalizations.

Outbreaks can be particularly burdensome, with up to  
**35,000** cases  
**in one month**  
in 2013<sup>(2)</sup>

Asia bears **70%**<sup>(3)</sup>  
of the global  
disease burden.  
Sanofi Pasteur has  
been committed  
to ensuring the  
vaccine is  
available first  
to those that  
live in endemic  
areas.



**65%**  
of dengue cases  
are hospitalized.<sup>(1)</sup>



causing  
on average  
an estimated

**4** | days  
inpatient<sup>(1)</sup>

**11** | days  
disability<sup>(1)</sup>

Up to  
**\$565**  
**USD**<sup>(1)</sup>

Estimated cost per  
hospitalized case.  
That's more than one  
month's income for  
the average family  
in the Philippines  
(although not all costs  
of hospitalization are  
borne by the patient).<sup>(5)</sup>

**VACCINATION  
CAN BE AN  
IMPORTANT  
NEW TOOL IN  
COMBINATION  
WITH OTHER  
DENGUE PREVENTION  
METHODS TO HELP  
CONTROL THE DISEASE.**

**THE VACCINE'S CLINICAL PROFILE WAS STUDIED FOR SAFETY AND EFFICACY  
AGAINST ALL 4 DENGUE VIRUS TYPES AMONG 40,000 PEOPLE FROM 15 COUNTRIES.  
THE PHILIPPINES PARTICIPATED IN ALL THREE PHASES OF CLINICAL TRIALS.<sup>(4)</sup>**

In clinical trials, vaccine efficacy among at-risk populations of 9 to 16 years old,  
over a 25-month period, following the first dose of the vaccine:

Severe cases



Hospitalized cases



Symptomatic cases



Pooled efficacy analysis in 9-16 year olds over a 25-month period, following first dose of the vaccine.  
Efficacy is extrapolated to individuals over 16 based on similar immune responses.

Sources:

1. Edillo, Frances, et al. Economic Cost and Burden of Dengue in the Philippines. Am. J. Trop. Med. Gyg. 92(2) 2015 pp 360-366
2. Department of Health National Epidemiology Center Public Health Surveillance and Informatics Division Disease surveillance report Morbidity week 46 November 10 - 16, 2013. Nec.doh.gov.ph. 02.651.7800.2930
3. Nature. 2013 Apr 25;496(7446):504-7
4. Hadinegoro, Sri Rezeki S., et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease Integrated Analysis of Efficacy and Interim Long-Term Safety Data for a Dengue Vaccine in Endemic Regions. July 27, 2015 DOI: 10.1056/NEJMoa1506223
5. National statistics office, 2012 Family Income and Expenditure Survey. https://psa.gov.ph/sites/default/files/attachments/hsd/article/TABLE%201%20Number%20of%20Families%2C%20Total%20and%20Average%20Annual%20Family%20Income%20and%20Expenditure%20by%20Region%202012\_0.pdf last accessed February 2016